Dr. Lu Zhenhai specializes in surgical treatment of colorectal cancer, particularly laparoscopic minimally invasive treatment of colorectal tumors and comprehensive treatment of colorectal cancer. His expertise includes early diagnosis, staging, treatment, and prognosis research of colorectal cancer, transformation research of colorectal cancer liver metastasis, as well as comprehensive treatment and multidisciplinary treatment of colorectal cancer. He also focuses on the comprehensive treatment of locally advanced rectal cancer, including the selection of neoadjuvant treatment regimens, surgical treatment, and postoperative adjuvant treatment. In addition, Dr. Lu conducts basic and clinical research on hereditary colorectal cancer and clinical research on gastrointestinal stromal tumors.

Colorectal Cancer Liver Metastasis; Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

In 2007, Dr. Lu Zhenhai received his Doctor of Medicine degree from Sun Yat-sen University Cancer Center. He has served as a visiting scholar at the Southern Health and Peter MacCallum Cancer Centre, Monash University, and Queen Mary Hospital, the University of Hong Kong.

1. Peng J, Ou Q, Deng Y, Xiao B, Zhang L, Li J, Li Y, Wan D, Lu Z, Fang Y. TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection. Ther Adv Med Oncol. 2019 Dec 31;11:1758835919897543. doi:10.1177/1758835919897543. PMID: 35173815; PMCID: PMC8842308.

2. Peng J, Zhang R, Zhao Y, Wu X, Chen G, Wan D, Lu Z, Pan Z. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer. Chin J Cancer. 2017 Dec 21;36(1):96. doi: 10.1186/s40880-017-0260-1. PMID: 29268783; PMCID: PMC5740941.

3. Wang F, Fan W, Peng J, Lu Z, Pan Z, Li L, Gao Y, Li H, Chen G, Wu X, Ding P, Zeng Z, Wan D. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial. Cancer Commun (Lond). 2018 Dec 20;38(1):73. doi: 10.1186/s40880-018-0342-8. PMID: 30572939; PMCID: PMC6302296.

4. Peng JH, Tai Y, Zhao YX, Luo BJ, Ou QJ, Pan ZZ, Zhang L, Lu ZH. Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection. Gastroenterol Rep (Oxf). 2020 Dec 10;9(5):443-450. doi: 10.1093/gastro/goaa077. PMID: 34733530; PMCID: PMC8560040.